SynthesisHead & neck2025
Surgical Versus Non-Surgical Treatment of Advanced Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Non-Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?Head & neck · 2026Review
- Comparison of surgical and non surgical treatment strategies for non metastatic oropharyngeal cancer using inverse probability weighting.Discover oncology · 2025Article
- Article
- Comparative Outcomes of Surgical vs. Non-Surgical Interventions in Advanced Oropharyngeal Cancer: A Large-Scale Retrospective Cohort Study.Laryngoscope investigative otolaryngology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis review aims to compare survival outcomes of surgical versus non-surgical treatment of advanced-stage OPSCC.
methodsCINAHL, Cochrane Library, PubMed, and Scopus were searched. Studies comparing the survival of patients with advanced OPSCC treated surgically (±adjuvant therapy) or non-surgically were included. Meta-analyses hazard ratio (HR) and proportions (%) were performed for the outcomes of 2-, 3-, and 5-year overall (OS), disease-free (DFS), disease-specific (DSS), and relapse-free (RFS) survival.
resultsForty-four studies reporting on (N = 35 681) patients were included, with a mean age of 58.9. For advanced-stage disease, primary treatment with surgery and chemoradiotherapy (CRT) demonstrated the best 5-year OS, at 67.1% (95% CI 55.6-77.6). Survival outcomes favored Surgery + CRT over other primary treatment modalities.
conclusionsSurgical treatment with adjuvant CRT may be associated with better OS outcomes compared with non-surgical treatment. Further research is needed to determine superior treatment modalities in OPSCC subgroups, such as HPV+ tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.